News / Taiwan / cnyes
Foresee Pharmaceuticals Reports 14% Revenue Decline, Eyes Growth from CAMCEVI 3-Month Formulation
Health Technology · Pharmaceuticals: Major · cnyes · 2026-09-10
6576
Foresee Pharmaceuticals' revenue for the first eight months of the year fell by 14.42%, but the company expects a rebound as its 3-month CAMCEVI formulation launches in the US and Europe.
What Happened
Revenue Performance: Foresee Pharmaceuticals reported August revenue of NT$26.72 million, marking a decline on both a monthly and annual basis. For the first eight months of the year, cumulative revenue reached NT$319 million, representing a 14.42% year-over-year decrease driven by its existing 6-month CAMCEVI formulation.
Market Expansion: Despite the recent revenue dip, the company is aggressively rolling out its 3-month CAMCEVI formulation following regulatory approvals in the US and Europe. With additional authorization in the UK and a pending application in Taiwan, the company aims to leverage its dual-formulation strategy to capture a larger market share.
Product Synergy: Management highlighted that the potential market for the 3-month formulation is significantly larger than that of the 6-month version. By integrating both products, Foresee expects to achieve operational synergies that will bolster its competitive standing and revenue growth in the oncology sector.
Future Outlook: The company plans to submit an FDA application for FP-001 42mg to treat central precocious puberty in the fourth quarter. With a dedicated marketing team currently being assembled, Foresee targets US regulatory approval by late 2027 to initiate its own direct sales operations.